DiscoverThe NRG Oncology PodcastNRG-BR008, The "HERO" Breast Cancer Trial
NRG-BR008, The "HERO" Breast Cancer Trial

NRG-BR008, The "HERO" Breast Cancer Trial

Update: 2025-02-05
Share

Description

The NRG Oncology Podcast Co-hosts sit with NRG-BR008 "HERO" Study Co-PIs Dr. Lior Braunstein and Dr. Melissa Mitchell to discuss this study for low-risk HER2+ breast cancer. This study will test if HER2-targeted therapy without radiation therapy is as good as the usual treatment of HER2-targeted therapy with radiation for patients with early-stage HER2+ breast cancer.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

NRG-BR008, The "HERO" Breast Cancer Trial

NRG-BR008, The "HERO" Breast Cancer Trial

NRG Oncology